Mikhail Blagosklonny is a distinguished oncology scientist with a focus on cancer and aging. He is the editor-in-chief of Oncotarget, a highly popular peer-reviewed online journal. The journal focuses on maximizing the impact of research. It aggregates scientific research papers on tumors. Besides, oncology, the journal also publishes peer-reviewed papers on other disciplines such as immunology, pathology, cardiology, and cell biology.
He also oversees Cell Cycle, a peer-reviewed journal that focuses on cell biology. He is associated with the renowned Roswell Park Cancer Institute. Mikhail Blagosklonny believes anti-aging therapies can be used to prolong the healthy lifespan in humans. He also asserts that such techniques can be useful in reducing the effects of numerous diseases. There exists a direct relationship between the aging process and diseases such as cancer, diabetes, and heart disease among others.
He is a strong advocate of Rapamycin, one of the groundbreaking drugs in commercial clinical use, to rejuvenate the immune system. It has become a popular choice for cancer therapy. Rapamycin is an excellent option for managing heart disease, osteoporosis, Alzheimer’s, and autoimmunity conditions. A good number of people succumb to age-related complications. The drug works by slowing down the detrimental effects of aging.
This can not only add to your lifespan but also reduce the development of age-related conditions such as cancer. These and other advanced therapies can target cancerous cells while minimizing the risk of damage to other healthy cells. This specificity is unparalleled and heralds a new phase in the search for a definitive cancer cure.
Mikhail Blagosklonny attended First Pavlov State Medical University in St. Petersburg, Russia. He has worked as an associate professor at New York Medical College. He later served as a senior researcher at Ordway Research Institute. He moved to the Roswell Park Cancer Institute in 2009. He has a strong focus on the development of anti-aging drugs and cancer therapies.
Mikhail Blagosklonny is involved in the editing and distribution of numerous peer-reviewed journals on oncology and related disciplines. He is on the editorial board of Cell Death and Differentiation, a peer-reviewed medical journal distributed by Nature Publishing. He is also associated with Plos One, a multidisciplinary open access journal. In addition, he is also on the editorial board of American Journal of Pathology, International Journal of Cancer and Cancer Biology & Therapy.
Mikhail Blagosklonny is renowned for his dedication and focus on oncology. He is committed to achieving a disease-free community. His leadership position at the Roswell Park has enabled him to advance the study of anticancer therapeutics. He was the head of the Department of Cell Stress Biology. The institute is one of the top-rated comprehensive cancer centers in the country. It is dedicated to the research, diagnosis, and treatment of cancer. Check Mikhail’s profile in LinkedIn
The goal is to transform simple science into emergent and commercially viable anti-cancer therapies. He has demonstrated expert research skills and editorial prowess. He has extensively written on anti-aging and cancer. Mikhail Blagosklonny has over three hundred published peer-reviewed papers. He remains an authority to watch on developments in anti-aging and cancer therapy.